ALVR (AlloVir) Utang jangka cendhak marang modal

AlloVir, Inc. (ALVR) relies on a universal cell therapy platform, enabling the rapid adaptation of treatments for various infections. The business focuses on assisting transplant patients while expanding its reach through biomedical development. However, the company is currently restructuring following unsuccessful tests, resulting in a loss of pricing power. The indicator stands at 0.00. The linear price action on the chart below reflects the issuer's current financial condition.

The short-term debt-to-equity ratio measures the proportion of current loans within the financing structure, allowing for an assessment of liquidity risk and the degree of the business's financial autonomy. Low reliance on borrowed capital is critically important for AlloVir, Inc., as the use of contract biocomplexes in the US minimizes capital expenditures on equipment, which is reflected in the stability of the short-term liabilities-to-equity ratio.